Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesInoviq Ltd

Inoviq Ltd

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.13 AUD 0.00(0%)
Last update at 2026-11-12T04:45:00Z
VOLUME
6691
Market Cap
19.00M

Momentum Score

…

INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium. It also offers non-invasive diagnostics using its proprietary exosome development technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.13
Low
0.13
High
52 Week Price Range
0.13
Low
0.56
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Inoviq Ltd is limited and available disclosures do not provide a clear description of its core operations; prospective investors should review the company's regulatory filings and investor presentations for specifics. Long-term value appears dependent on execution of any stated strategy, commercialisation progress, and access to capital, which could support growth if achieved.
Primary investment risks include opaque public information, execution and financing risk, and potential low liquidity in the stock.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.13
Dividend Yield
-
Revenue TTM
2.21M
Revenue Per Share
0.02
Gross Profit TTM
-2.53M
Debt / Equity
0.02
ROE
-42.16%
Net Debt
-9.06M
ROCE
-50.36%
Diluted EPS TTM
-0.06

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -9.29M -6.93M -6.55M -10.06M -8.57M
Net income -7.51M -6.93M -6.55M -8.97M -6.51M
Selling general administrative - 5.31M 3.21M 3.40M 2.22M
Selling and marketing expenses - 0.47M 0.43M 0.77M 0.55M
Gross profit -0.97M -1.56M 0.45M -1.04M 0.22M
Reconciled depreciation - - 1.20M 1.15M 1.96M
Ebit -9.67M -7.34M -7.54M -10.42M -8.08M
Ebitda -8.34M -6.16M -6.34M -9.02M -6.18M
Depreciation and amortization 1.33M 1.19M 1.20M 1.39M 1.89M
Operating income -9.67M -10.60M -7.80M -10.42M -8.08M
Other operating expenses 10.10M 12.41M 8.37M 10.81M 9.50M
Interest expense 0.02M 0.02M 0.04M 0.06M 0.08M
Tax provision - 0.00M 0.00M 0.00M -2.06M
Interest income - - 0.26M 0.35M 0.07M
Net interest income - - 0.26M 0.35M -0.02M
Income tax expense -1.78M - -1.03M -1.09M -2.06M
Total revenue 0.43M 1.82M 0.54M 0.40M 0.28M
Total operating expenses 8.69M 9.04M 8.29M 9.38M 9.44M
Cost of revenue 1.41M 3.37M 0.08M 1.44M 0.06M
Total other income expense net 0.38M 3.67M 1.28M 0.35M 0.58M
Net income from continuing ops - - -6.55M -8.97M -18.20M
Net income applicable to common shares - -6.93M -6.55M -8.97M -18.20M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 20.45M 18.46M 21.71M 21.51M 30.78M
Intangible assets 7.72M 8.68M - 10.65M 12.32M
Other current assets 0.35M 1.97M 0.33M - 0.35M
Total liab 1.56M 1.74M 1.72M 1.89M 2.49M
Total stockholder equity 18.89M 16.71M 19.99M 19.62M 28.29M
Other current liab 0.92M 0.97M 0.54M - 0.42M
Common stock 87.65M 78.05M 75.13M 69.05M 69.05M
Capital stock - - - 69.05M 69.05M
Retained earnings -70.20M -63.00M -56.92M -51.07M -30.18M
Other liab - - - 0.01M 0.05M
Good will - - - 0.00M 11.03M
Other assets - - 0.00M - -
Cash 9.35M 6.52M 9.23M 7.81M 15.39M
Cash and equivalents - - - 7.81M 15.39M
Total current liabilities 1.26M 1.51M 1.53M 1.52M 1.80M
Net debt -9.06M -6.14M -8.70M - -14.40M
Short term debt 0.06M 0.20M 0.37M 0.00M 0.36M
Short long term debt total 0.29M 0.38M 0.54M - 1.00M
Other stockholder equity - - - 1.63M -11.68M
Property plant equipment - - - 1.45M 1.65M
Total current assets 11.76M 8.70M 10.86M 9.40M 17.47M
Net tangible assets - - - 8.96M 16.63M
Net receivables 2.02M 0.16M 1.27M 1.19M 1.71M
Inventory 0.04M 0.05M 0.02M 0.02M 0.01M
Accounts payable 0.28M 0.35M 0.63M 0.47M 1.02M
Accumulated other comprehensive income 1.44M 1.66M 1.78M - 1.10M
Non currrent assets other - - 9.70M - -11.68M
Non current assets total 8.69M 9.75M 10.85M 12.11M 13.31M
Capital lease obligations - - - 0.73M 1.00M
Long term debt total - - - 0.37M 0.64M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - -0.17M -0.29M -0.41M
Change to liabilities - - - -0.21M 0.28M
Total cashflows from investing activities -0.17M -0.10M -0.17M -0.29M -0.41M
Net borrowings - - - -0.27M -0.27M
Total cash from financing activities 9.39M 2.05M 5.91M -0.27M 16.87M
Change to operating activities - - - -0.09M 0.09M
Net income -7.51M -6.93M -6.55M -8.97M -18.20M
Change in cash 2.83M -2.71M 1.42M -7.58M 10.40M
Begin period cash flow 6.52M 9.23M 7.81M 15.39M 5.00M
End period cash flow 9.35M 6.52M 9.23M 7.81M 15.39M
Total cash from operating activities -6.38M -4.66M -4.32M -7.02M -6.06M
Issuance of capital stock - - 6.75M - 18.46M
Depreciation 1.33M 1.38M 1.44M 1.39M 2.10M
Other cashflows from investing activities - - -0.01M -0.02M -0.13M
Dividends paid - - - - 0.27M
Change to inventory 0.01M -0.03M -0.00M -0.00M 0.03M
Change to account receivables -0.39M -0.40M 0.02M 0.46M -1.49M
Sale purchase of stock - 2.63M -0.51M 0.00M -1.24M
Other cashflows from financing activities -0.22M -0.33M -0.33M -0.27M -0.08M
Change to netincome - - - 0.39M 11.03M
Capital expenditures 0.17M 0.10M 0.17M 0.29M 0.41M
Change in working capital -0.33M -0.25M 0.09M 0.16M -1.08M
Stock based compensation - 0.82M 0.83M 0.33M 0.30M
Other non cash items 0.12M 0.32M -0.14M 2.94M 16.48M
Free cash flow -6.55M -4.77M -4.50M -7.32M -6.47M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IIQ
Inoviq Ltd		 -
-%		 0.13 - - 8.58 0.97 21.38 -3.23
SHL
Sonic Healthcare Ltd		 0.09
0.45%		 19.92 16.16 17.21 0.90 1.15 1.36 8.10
IDX
Integral Diagnostics Ltd		 -
-%		 1.70 28.83 15.24 0.82 0.97 1.52 9.49
ACL
Australian Clinical Labs Ltd		 0.01
0.30%		 3.33 26.67 16.84 0.81 3.95 1.24 5.12
HLS
Healius Ltd		 0.01
2.86%		 0.54 - 29.24 0.26 2.08 0.94 10.14

Profile*

Inoviq Ltd

INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium. It also offers non-invasive diagnostics using its proprietary exosome development technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.

23 Normanby Road, Notting Hill, VIC, Australia, 3168

61 3 9548 7586

https://www.inoviq.com

Name Title Year Born
Dr. Leearne Maree Hinch B.Sc., B.V.M.S., BSc., M.B.A., M.R.C.V.S. Chief Exec. Officer NA
Prof. Gregory Edward Rice BSc (Hons), GradDipMgt, MHA, Ph.D. Chief Scientific Officer NA
Mr. Mark Edwards BAcc, C.A., CA CFO & Company Sec. NA
Dr. Leearne Maree Hinch B.Sc., B.V.M.S., BSc., M.B.A., M.R.C.V.S. Chief Executive Officer NA
Mr. Mark Edwards BAcc, C.A., CA CFO & Company Secretary NA
Dr. Leearne Maree Hinch B.Sc., B.V.M.S., BSc., M.B.A., M.R.C.V.S. Chief Executive Officer NA
Mr. Mark Edwards BAcc, C.A., CA CFO & Company Secretary NA
Dr. Leearne Maree Hinch B.Sc., B.V.M.S., BSc., M.B.A., M.R.C.V.S. Chief Executive Officer NA
Mr. Mark Edwards BAcc, C.A., CA CFO & Company Secretary NA
Dr. Leearne Maree Hinch B.Sc., B.V.M.S., BSc., M.B.A., M.R.C.V.S. Chief Executive Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…